Patrick Julier

• Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.

  Kerr RS. et al, (2016), The Lancet. Oncology, 17, 1543 - 1557

• A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.

  Rosmarin D. et al, (2015), Gut, 64, 111 - 120

• Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.

  Dutton SJ. et al, (2014), The Lancet. Oncology, 15, 894 - 904

• Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.

  Rosmarin D. et al, (2014), Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32, 1031 - 1039

• Phase II clinical trial of six mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumors.

  Nicum S. et al, (2013), JOURNAL OF CLINICAL ONCOLOGY, 31

• Patient-reported outcomes from a phase HI multicenter, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing alter chemotherapy: Cancer Oesophagus Gefitinib (COG)

  Dutton SJ. et al, (2013), JOURNAL OF CLINICAL ONCOLOGY, 31

• CAPECITABINE (CAPE) +/- BEVACIZUMAB (BEV) IN THE ADJUVANT TREATMENT OF COLORECTAL CANCER (CRC) FIRST AND FINAL TOXICITY RESULTS FROM THE INTERNATIONAL PHASE III QUASAR2 TRIAL

  Midgley RS. et al, (2012), ANNALS OF ONCOLOGY, 23, 181 - 182

• Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.

  Midgley RS. et al, (2010), Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28, 4575 - 4580

• VICTOR: A PHASE III PLACEBO-CONTROLLED TRIAL OF ROFECOXIB IN COLORECTAL CANCER PATIENTS FOLLOWING SURGICAL RESECTION

  Midgley RSJ. et al, (2008), ANNALS OF ONCOLOGY, 19, 1 - 1

• Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.

  Kerr DJ. et al, (2007), The New England journal of medicine, 357, 360 - 369

Recent Publications

• Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.

  Kerr RS. et al, (2016), The Lancet. Oncology, 17, 1543 - 1557

• A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.

  Rosmarin D. et al, (2015), Gut, 64, 111 - 120

• Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.

  Dutton SJ. et al, (2014), The Lancet. Oncology, 15, 894 - 904

• Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.

  Rosmarin D. et al, (2014), Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32, 1031 - 1039

• Phase II clinical trial of six mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumors.

  Nicum S. et al, (2013), JOURNAL OF CLINICAL ONCOLOGY, 31